Potential Silver Bullet for Swine Flu and Most Common Infections Using Green Technology...

Potential Silver Bullet for Swine Flu and Most Common Infections Using Green
Technology Patented in U.S. and Mexico

FORT LAUDERDALE, Fla., June 24 /PRNewswire/ -- Argentech, Inc.
(www.argentechinc.com) today announced that it reached agreement with Invision
International Health Solutions, Inc., to purchase the rights to Opti-Silver, a
patented antibacterial and antiviral technology that utilizes ionic silver in
a unique complex for optimal delivery in the human body. The complex was
granted broad patent protection in the U.S. and, recently, in Mexico as well.
It also has patent protection overseas. (See www.silver100.com/patents.)

Recently, there has been a surge in the number of industrial and medically
related products utilizing ionic silver, owing to its broad-spectrum
antibacterial and antiviral qualities. University studies and regulatory
approvals further attest to the antimicrobial powers of ionic silver, which is
harmless to humans with normal use.

The mechanism of action by which ionic silver kills germs gives it this
remarkable combination of characteristics. However, it's extremely unstable
and requires a delivery mechanism to function.

The result of more than a million dollars in development, Opti-Silver was
designed explicitly to optimize the delivery of silver ions in the human body.

"The Opti-Silver complex represents a quantum leap in utilizing ionic silver
for internal human use," said Roger Leblanc, Ph.D., former director of the
Departments of Chemistry and Advanced Microscopy at the University of Miami.
"Nothing else even comes close to the efficiency of its unique delivery
mechanism."

Donald Baird, Ph.D., former director of the Department of Chemistry at Florida
Atlantic University, has called Opti-Silver "ingenious" and "unprecedented."
(See www.silver100.com/reports.)

In November of 2007, the maker of a certain surface disinfectant was granted
EPA approval to claim that its ionic silver product kills strains of SARS,
Bird Flu, MRSA, influenza, and a range of other pathogens. Drs. Leblanc and
Baird have written pointed reports stating that that surface disinfectant
would be all but useless for internal human use, citing its lack of an
appropriate delivery mechanism for the challenging electro-chemical
environment of the human body.

"To a chemist," Dr. Baird stated, "Opti-Silver represents a brilliant chemical
formulation that results in a far more efficient delivery mechanism for
releasing silver ions in the body than has ever existed before."

"We have the technology and patents to support a business model that enables
us to perform serious humanitarian work, by growing our business," said Jay
Newman, CEO of Argentech. "And we have a game plan in place to roll this out
to the public on a massive scale in a remarkably short time," he said.

A study has been designed, to be conducted at the world's largest clinical
research center for pediatric drugs, which Argentech believes will prove the
ability of ionic silver to prevent the vast majority of upper respiratory
infections, including those that are viral in nature. Fighting viral infection
is an area where solutions are still lacking and vitally needed.

"To fund the study, we're relying on wealthy individuals who really want to
make a difference in human health on a worldwide scale," Newman said.

"It's not that we mind sharing stock with investors," he added. "We find that
philanthropists tend to resonate far better with us, because they share the
humanitarian priority behind our mission. It's not just about the numbers for
us. It's both. We have to be successful to get this vital product to the
people."

Charitable contributions can be made into a 501(C)(3) called the Foundation
for Health Research, which will fund the study.

Meet Newman and hear the story at www.argentechinc.com/video1.

This release was issued on behalf of the above organization by Send2Press(R),
a unit of Neotrope(R). http://www.Send2Press.com

SOURCE Argentech, Inc.

Jay Newman of Argentech, Inc., +1-954-776-2406, jnewman@argentechinc.com